Optimization of the cycling of clonogenic and primitive cord blood progenitors by various growth factors

Stem Cells
M MovassaghF M Lemoine

Abstract

The cycling status of cord blood progenitors and the culture conditions triggering their activation into S-phase have been studied using flow cytometry and a 3H-thymidine suicide assay. Mononuclear cells cultured either in Iscove's modified Dulbecco's medium (IMDM) +/- 10% fetal calf serum ([FCS]; IMDM + FCS) or in Dulbecco's modified Eagle's medium (DMEM) +/- 10% newborn bovine serum ([NBS]; DMEM + NBS) were stimulated by various growth factors (GFs). Results showed that CD34+ cells, clonogenic progenitors (colony forming cells [CFCs]) and long-term culture initiating cells (LTC-IC) present in freshly harvested cord blood were quiescent. CFC numbers were maintained without cycling after 48-h cultures in serum-containing media without GFs. Addition of interleukin 3 (IL-3) + IL-6 + stem cell factor stimulated into S-phase approximately 40% of CFCs within 24-48 h, without modifying their number except in DMEM + NBS where erythroid progenitors decreased. When cells were stimulated in IMDM + FCS by these three GFs + insulin-like growth factor I and basic fibroblast growth factor used at high concentration, more than 50% of CFCs were in S-phase and their total number was maintained. The latter culture conditions also recruited up to...Continue Reading

References

May 1, 1992·Proceedings of the National Academy of Sciences of the United States of America·A G LearyM Ogawa
Jun 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·A G LearyM Ogawa
Dec 1, 1988·Molecular and Cellular Biology·J W BelmontC T Caskey
Sep 1, 1988·Proceedings of the National Academy of Sciences of the United States of America·O Danos, R C Mulligan
Sep 1, 1993·The Journal of Experimental Medicine·P M LansdorpH Mayani
Aug 1, 1993·Proceedings of the National Academy of Sciences of the United States of America·M CarusoD Klatzmann

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.